Evidence map›Paper›PMID 21177283›Full record

ArticleProtein engineering, design & selection : PEDS2011

Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune molecules.

Richard L Wong, Bai Liu, Xiaoyun Zhu, Lijing You, Lin Kong, Kai-Ping Han, Hyung-Il Lee, Pierre-Andre Chavaillaz, Moonsoo Jin, Yi Wang and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Article
  3. Immunotherapy of Childhood Sarcomas.Frontiers in oncology · 2015
    Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Richard L WongDepartment of Biomedical Engineering, Cornell University, Ithaca, NY 14850, USA.
Bai Liu
Xiaoyun Zhu
Lijing You
Lin Kong
Kai-Ping Han
Hyung-Il Lee
Pierre-Andre Chavaillaz
Moonsoo Jin
Yi Wang
Peter R Rhode
Hing C Wong
Altor BioScience (United States) · USCornell University · US

Funding

Soluble TCR-IL15 Fusions as Targeted Therapeutics for CancerR43CA139810 · NCI · ALTOR BIOSCIENCE. LLC · PI RHODE, PETER R · 2009 to 2009
$203k
NCI NIH HHS R43 CA139810
6 · The paper itself

Abstract

Human interleukin-15 (hIL-15) and its receptor α (hIL-15Rα) are co-expressed in antigen presenting cells allowing trans-presentation of the cytokine to immune effector cells. We exploited the high-affinity interactions between hIL-15 and the extracellular hIL-15Rα sushi domain (hIL-15RαSu) to create a functional scaffold for the design of multispecific fusion protein complexes. Using single-chain T cell receptors (scTCRs) as recognition domains linked to the IL-15:IL-15Rα scaffold, we generated both bivalent and bispecific complexes. In these fusions, the scTCR domains retain the antigen-binding activity and the hIL-15 domain exhibits receptor binding and biological activity. As expected, bivalent scTCR fusions exhibited improved antigen binding due to increased avidity, whereas fusions comprising two different scTCR domains were capable of binding two cognate peptide/MHC complexes. Bispecific molecules containing scTCR and scCD8αβ domains also exhibit enhanced binding to peptide/MHC complexes, demonstrating that the IL-15:IL-15Rα scaffold displays flexibility necessary to support multi-domain interactions with a given target. Surprisingly, functional heterodimeric molecules could be formed by co-expressing the TCR α and β chains separately as fusions to the hIL-15 and hIL-15RαSu domains. Together, these properties indicate that the hIL-15 and hIL-15RαSu domains can be used as versatile, functional scaffold for generating novel targeted immune molecules.

Indexed as

Cells, CulturedHumansInterleukin-15Protein MultimerizationProtein Structure, TertiaryReceptors, Interleukin-15Recombinant Fusion ProteinsInterleukin-15Receptors, Interleukin-15Recombinant Fusion Proteins

Identifiers

PMID21177283
PMCPMC3049345
OpenAlexW2158885737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.